Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr;189(2):291-302.
doi: 10.1111/bjh.16380. Epub 2020 Jan 16.

Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera

Ayalew Tefferi  1 , Paola Guglielmelli  2 , Terra L Lasho  1 , Giacomo Coltro  2 , Christy M Finke  1 , Giuseppe G Loscocco  2 , Benedetta Sordi  2 , Natasha Szuber  1 , Giada Rotunno  2 , Annalisa Pacilli  2 , Curtis A Hanson  3 , Rhett P Ketterling  4 , Animesh Pardanani  1 , Naseema Gangat  1 , Alessandro M Vannucchi  2
Affiliations

Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera

Ayalew Tefferi et al. Br J Haematol. 2020 Apr.

Abstract

Survival prediction in essential thrombocythaemia (ET) and polycythaemia vera (PV) is currently based on clinically-derived variables; we examined the possibility of integrating genetic information for predicting survival. To this end, 906 molecularly-annotated patients (416 Mayo Clinic; 490 University of Florence, Italy), including 502 ET and 404 PV, were recruited. Multivariable analysis identified spliceosome mutations to adversely affect overall (SF3B1, SRSF2 in ET and SRSF2 in PV) and myelofibrosis-free (U2AF1, SF3B1 in ET) survival; TP53 mutations predicted leukaemic transformation in ET; "adverse" mutations occurred in 51 (10%) ET and 8 (2%) PV patients. We confirmed the independent survival effect of adverse mutations [hazard ratio (HR) 2·4, 95% CI 1·6-3·5], age >60 years (6·6, 4·6-9·7), male sex (1·8, 1·3-2·4) and leukocytosis ≥11 × 109 /l (1·6, 1·1-2·2), in ET, and adverse mutations (7·8, 3·1-17·0), age >67 years (5·4, 3·6-8·1), leukocytosis ≥15 × 109 /l (2·8, 1·8-4·2) and thrombosis history (2·0, 1·4-2·9), in PV. HR-based risk point allocation allowed development of three-tiered mutation-enhanced international prognostic systems (MIPSS) which were validated in both cohorts and performance was shown to be superior to conventional scoring systems. Spliceosome mutations enhance survival prediction in ET and PV and identify patients at risk for fibrotic progression. TP53 mutations predict leukaemic transformation in ET.

Keywords: karyotype; leukemia; mutation; myelofibrosis; prognosis; survival.

PubMed Disclaimer

References

    1. Arber, D.A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M.J., le Beau, M.M., Bloomfield, C.D., Cazzola, M. & Vardiman, J.W. (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127, 2391-405.
    1. Barbui, T., Thiele, J., Passamonti, F., Rumi, E., Boveri, E., Ruggeri, M., Rodeghiero, F., D'Amore, E.S., Randi, M.L., Bertozzi, I., Marino, F., Vannucchi, A.M., Antonioli, E., Carrai, V., Gisslinger, H., Buxhofer-Ausch, V., Mullauer, L., Carobbio, A., Gianatti, A., Gangat, N., Hanson, C.A. & Tefferi, A. (2011) Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. Journal of Clinical Oncology, 29, 3179-3184.
    1. Barosi, G., Mesa, R.A., Thiele, J., Cervantes, F., Campbell, P.J., Verstovsek, S., Dupriez, B., Levine, R.L., Passamonti, F., Gotlib, J., Reilly, J.T., Vannucchi, A.M., Hanson, C.A., Solberg, L.A., Orazi, A., Tefferi, A.; International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). (2008) Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia, 22, 437-438.
    1. Barraco, D., Cerquozzi, S., Hanson, C.A., Ketterling, R.P., Pardanani, A.D., Gangat, N. & Tefferi, A. (2017) Cytogenetic findings in WHO-defined polycythaemia vera and their prognostic relevance. British Journal of Haematology, 182, 437-440.
    1. Cerquozzi, S. & Tefferi, A. (2015) Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer Journal, 5, e366.

Publication types